前列腺癌原发及转移性非去势与去势抵抗状态的基因组特征:183例患者的新一代测序研究
该研究对183例前列腺癌患者进行新一代测序,包括原发腺癌97例、局部晚期12例、转移性非去势21例和去势抵抗54例。发现TP53改变在高危原发癌中富集,TP53/RB1改变在高级别神经内分泌疾病中富集,AR改变在转移和去势抵抗疾病中富集。约五分之一病例存在可操作改变(MSI-H表型和HRR基因)。
要点
- TP53改变在高危原发前列腺癌中富集。
- TP53/RB1改变在高级别神经内分泌疾病中富集。
- AR改变在转移性和去势抵抗性疾病中富集。
核心结论
- 这些结果有助于阐明前列腺癌临床谱系中的基因组改变全景。
研究设计与样本
- 对183例前列腺癌患者的新一代测序结果进行评价,包括原发腺癌97例、局部晚期疾病(累及膀胱/直肠)12例、转移性非去势21例和去势抵抗54例。
主要发现
- TP53改变在高危原发前列腺癌中富集。
- TP53/RB1改变在高级别神经内分泌疾病中富集。
- AR改变在转移性和去势抵抗性疾病中富集。
- 可操作改变(MSI-H表型和HRR基因)在约五分之一的所有病例中被识别。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Primary prostatic adenocarcinoma (pPC) undergoes genomic evolution secondary to therapy-related selection pressures as it transitions to metastatic noncastrate (mNC-PC) and castrate resistant (mCR-PC) disease. Next generation sequencing results were evaluated for pPC (n = 97), locally advanced disease (involving urinary bladder/rectum, n = 12), mNC-PC (n = 21), and mCR-PC (n = 54). We identified enrichment of TP53 alterations in high-grade pPC, TP53/RB1 alterations in HGNE disease, and AR alterations in metastatic and castrate resistant disease. Actionable alterations (MSI-H phenotype and HRR genes) were identified in approximately a fifth of all cases. These results help elucidate the landscape of genomic alterations across the clinical spectrum of prostate cancer.
引用
- Dasari S, McCarthy MR, Wojcik AA, et al. Genomic attributes of prostate cancer across primary and metastatic noncastrate and castrate resistant disease states: a next generation sequencing study of 183 patients. Prostate Cancer Prostatic Dis. 2024. PMID: 38413763. doi:10.1038/s41391-024-00814-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。